Press release
Imatinib Drug Market 2025 | Investment Opportunities, Market Size & Future Opportunities
Market Size and GrowthThe Global Imatinib Drug Market is estimated to reach at a Significant CAGR during the forecast period (2024-2031).
Key Development:
✅ In August 2025, a study by Kidoguchi et al. in Internal Medicine reported that although generic imatinib has been available in Japan since 2014 at about 50-55% of the original price, brand-name Gleevec® still held ~72% market share in Fiscal Year 2022. One factor highlighted is Japan's universal health insurance and high-cost reimbursement systems that reduce out-of-pocket costs for patients.
✅ In November 2024, the FDA approved IMKELDI, an oral liquid formulation of imatinib, for treatment of certain forms of leukemia and other cancers. This is the first oral liquid tyrosine kinase inhibitor (TKI) form of imatinib meant to improve dosing accuracy and help patients (including children) who have difficulty swallowing tablets
✅ In October 2024, Japan implemented the Selective Treatment Fee (SENTEI RYOYOHI) rule, which requires patients who choose Gleevec® over its generic counterparts to pay 25% of the cost difference between Gleevec® and the most expensive generic imatinib. This policy aims to curb healthcare costs while preserving choice.
✅ In October 2024, Inhibikase Therapeutics closed financing of up to US$275 million, to advance IkT-001Pro (a prodrug formulation of imatinib) into late-stage clinical trials for pulmonary arterial hypertension (PAH). The aim is to mitigate safety and tolerability issues seen with earlier imatinib formulations.
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/imatinib-drug-market?sb
Imatinib is a targeted cancer therapy drug classified as a tyrosine kinase inhibitor, primarily used to treat chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GISTs), and other cancers. It works by blocking abnormal proteins that promote cancer cell growth, making it a breakthrough in precision oncology.
Key Players:
-> Sun Pharmaceutical Industries Ltd., Novartis AG, Dr. Reddy's Laboratories Ltd, Teva Pharmaceutical Industries Ltd., Mylan N.V., Cipla Inc, and Apotex Inc, Sanofi S.A., Actavis Generics, and others.
Growth Forecast Projected:
The Global Imatinib Drug Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.
Research Process:
Both primary and secondary data sources have been used in the global Imatinib Drug Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=imatinib-drug-market
Key Segments:
By Application: Chronic Eosinophilic Leukemia, Philadelphia Positive Chronic Myeloid Leukemia, Hyper-Eosinophilic Syndrome (HES), Myelodysplastic Syndrome (MDS), Myeloproliferative Diseases (MPD), Gastrointestinal Stromal Tumors (GIST), Others
By Drug Formulation: Capsules, Tablets
By End Use: Hospital Pharmacies, Ambulatory Surgical Centers, Clinics, Others
Regional Analysis for Imatinib Drug Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Benefits of the Report:
Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.
Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.
Chapter 3: Offers an in-depth look at the competitive landscape among Imatinib Drug producers, including revenue shares, strategic moves, and recent mergers and acquisitions.
Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.
Chapters 5 & 6: Analyze Imatinib Drug revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.
Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.
Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.
Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.
Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.
Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/imatinib-drug-market?sb
Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring
Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Imatinib Drug Market 2025 | Investment Opportunities, Market Size & Future Opportunities here
News-ID: 4186554 • Views: …
More Releases from DataM intelligence 4 Market Research LLP
United States Bladder Cancer Vaccines Market 2025 | Growth Drivers, Key Players …
Market Size and Growth
The Global Bladder Cancer Vaccines market reached US$254 million in 2024, up from US$209 million in 2023, and is projected to reach US$1,446 million by 2033, growing at a robust CAGR of 21.32% from 2025 to 2033.
Key Development & Recent Mergers and acquisitions:
United States: Recent Industry Developments
✅ In September 2025, the U.S. FDA approved the Gemcitabine intravesical system (InlexzoTM), previously TAR-200, for adult patients with BCG-unresponsive…
United States Peptide Synthesis Market 2025 | Growth Drivers, Key Players & Inve …
Market Size and Growth
The Global Peptide Synthesis market reached US$ 780.00 million in 2023, with a rise to US$ 860.99 million in 2024, and is expected to reach US$ 2,268.16 million by 2033, growing at a CAGR of 11.4% during the forecast period 2025-2033.
Key Development:
United States: Recent Industry Developments
✅ In October 2025, Cambrex announced a US $120 million investment to expand its API and peptide-manufacturing capacity at its Charles…
United States Vaccine Adjuvants Market to hit $1,280.35 million by 2033 - Exclus …
"The global vaccine adjuvants market size reached US$ 703.15 Million in 2024 from US$ 661.09 Million in 2023 and is expected to reach US$ 1,280.35 Million by 2033, growing at a CAGR of 6.9% during the forecast period 2025-2033." As per DataM intelligence research report
Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/vaccine-adjuvants-market
United States: Recent Industry Developments
✅ In June 2025, the U.S. vaccine adjuvants market reached around…
United States Sterile Injectables Market to hit $1,072.97 million by 2033 - Excl …
"The Global Sterile Injectables Market reached US$ 542.79 Million with a rise of US$ 578.61 Million in 2024 and is expected to reach US$ 1072.97 Million by 2033, growing at a CAGR of 7.15% during the forecast period 2025-2033." As per DataM intelligence research report
Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/sterile-injectable-market?sp
United States: Recent Industry Developments
✅ In September 2025, Pfizer Inc. expanded its sterile injectables manufacturing…
More Releases for Imatinib
Imatinib Mesylate Drugs Market By Industry Research, Supply, Size, Share and Pro …
The "Imatinib Mesylate Pharmaceuticals Market" 2023 research report offers insight into a global business study with key competitors functioning in the sector and a look at how the market will likely compete in the future. The Imatinib Mesylate Drugs market report created by our experts is a fantastic piece of work that takes into account obstacles and chances while also considering the growth of Imatinib Mesylate Drugs, shares, and revenue…
Imatinib Drug Market Report- Business Review, Technology, Top Companies and Tren …
The Imatinib Drug Market research report studies the competitive development of the Imatinib Drug Market, such as agreements, new product launches, expansions, and acquisitions in the market. In addition, Imatinib Drug Market provides a region-wise study of the market, including North America, Asia Pacific, Latin America, Middle East, Africa, and Europe. It helps stakeholders understand market players and analyze the top 25 organizations based on their product footprint, market strength,…
Global Imatinib Drug Market Size | COVID-19 Impact Analysis | Forecast to 2027
The global imatinib drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factor that is expected to accelerate the growth of the market includes an increase in the prevalence of cancer and an increase in demand for target drug therapy. For instance, according to National Cancer Institute in 2017, the number of new leukemia cases was 62,130 and the number of mortalities…
Imatinib Drug Market Growth, Size, Share, Industry Report and Forecast 2020-2026
FDA approval of imatinib drug for the treatment of different types of cancers by the major players propelling the growth of the imatinib drug market. For instance, in July 2019, Lupin Ltd. announced the launch of Imatinib Mesylate tablets, 100mg (base) and 400 mg (base). Lupin alliance partner Natco had received approval from the US FDA earlier. Lupin’s Imatinib Mesylate Tablet, 100 mg (base) and 400 mg (base) is the…
Imatinib Drug Market Size, Share, Growth, Industry Analysis, Opportunities and F …
FDA approval of imatinib drug for the treatment of different types of cancers by the major players propelling the growth of the imatinib drug market. For instance, in July 2019, Lupin Ltd. announced the launch of Imatinib Mesylate tablets, 100mg (base) and 400 mg (base). Lupin alliance partner Natco had received approval from the US FDA earlier. Lupin’s Imatinib Mesylate Tablet, 100 mg (base) and 400 mg (base) is the…
Imatinib Drug Market Size, Competitive Analysis, Share, Forecast- 2020-2026
The global imatinib drug market is estimated to grow at a CAGR of around 4% during the forecast period. The major factors contributing to the growth of the market include the rising prevalence of cancer and an increase in awareness programs towards cancer by government and private organizations. Imatinib is a chemotherapy drug that used to slow down or stopping the growth of the cancer cells. This medication is used…
